Sanofi to Buy US Blood Disorder Drugmaker for Up to $9.5 Billion
- Miguel Virgen, PhD Student in Business
- Aug 22, 2025
- 8 min read
French pharmaceutical giant Sanofi on June 2, 2025 announced an agreement to acquire Blueprint Medicines, a U.S.-based biopharma company known for its work on KIT-driven diseases and systemic mastocytosis, in a deal valued at roughly $9.1 billion in cash up front and up to about $9.5 billion including contingent milestone payments (Reuters). The transaction—priced at $129 per share in cash plus contractual contingent rights tied to future milestones—represents a bold strategic move by Sanofi to beef up its immunology and rare-disease portfolio and to add a commercialized medicine and promising R&D programs to its pipeline. The bid underscores how major pharma companies continue to pursue targeted acquisitions to replenish pipelines, gain footholds in specialty markets, and buy time while early-stage research advances.
Want to read more?
Subscribe to doctorsinbusinessjournal.com to keep reading this exclusive post.
